Clinical Stage Formulation to Treat Herpes Simplex 1 and 2

More than 9 Million people in the US suffer 6 or greater herpes labialis outbreaks every year with no existing medications indicated for the prevention of additional occurrences.

In this interview, Dr. Hugh McTavish, Company Founder, President, and CEO of Squarex, LLC, a  clinical-stage pharmaceutical company, talks about the company developing a topical formulation for the prevention of recurrent cold sores (herpes labialis) and other infections caused by Herpes Simplex Virus 1 or Herpes Simplex Virus 2.

Company Founder, President and CEO Dr. Hugh McTavish, suffered from frequent cold sores and developed this product to treat himself. Squarex is a clinical stage pharmaceutical company developing a topical formulation of the immunomodulator squaric acid dibutyl ester for the prevention of recurrent cold sores (herpes labialis) and other infections caused by Herpes Simplex Virus 1 or Herpes Simplex Virus 2. The compound is in early pre-clinical studies for the prevention of genital herpes. Unlike current treatments for cold sores, this compound is not applied to the face or lips. Rather, it’s on the arm or another part of the body.

Liked it? Take a second to support healthprofessionalradio on Patreon!

0 Comments

Leave a Reply

You must be logged in to post a comment.